Showing 17 of 37 recruiting trials for “nodular-lymphocyte-predominant-hodgkin-lymphoma”
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
👨⚕️ Ramya M Ramaswami, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Jun 2023View details ↗
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
👨⚕️ Yuankai Shi, MD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences📍 1 site📅 Started May 2023View details ↗
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
👨⚕️ Jason Westin, MD, MS, FACP, M.D. Anderson Cancer Center📍 1 site📅 Started Apr 2023View details ↗
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
👨⚕️ Lapo Alinari, MD, PhD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Mar 2023View details ↗
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
👨⚕️ Catherine S Diefenbach, Laura and Isaac Perlmutter Cancer Center at NYU Langone📍 9 sites📅 Started Nov 2022View details ↗
Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
👨⚕️ Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC📍 31 sites📅 Started Aug 2022View details ↗
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
👨⚕️ Wenbin Qian, 2nd Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Jul 2022View details ↗
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
👨⚕️ Christopher J Melani, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Feb 2018View details ↗
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
← PreviousPage 2 of 2
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →